Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203333 | 0.88 | KDM4E (0.31) | HSP90AA1KDM4ENAPRTHCAR2ADORA3 | |
| SCHEMBL1919145 | 0.78 | KDM4E (0.33) | HSP90AA1KDM4ENAPRTHCAR2ADORA3 | |
| SCHEMBL8427620 | 0.78 | LMNA (0.37) | HSP90AA1KDM4ENAPRTHCAR2ADORA3 | |
| Bromide SCHEMBL15567663 | 0.77 | KDM4E (0.32) | HSP90AA1KDM4ENAPRTHCAR2ADORA3 | |
| SCHEMBL11842818 | 0.74 | ATM (0.39) | HSP90AA1KDM4ENAPRTHCAR2ATM | |
| SCHEMBL7746776 | 0.74 | KDM4E (0.42) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL1521408 | 0.72 | HSP90AA1 (0.43) | HSP90AA1KDM4ENAPRTHCAR2ADORA3 | |
| SCHEMBL1515803 | 0.71 | SLC6A2 (0.39) | KDM4ELMNA | |
| SCHEMBL8282922 | 0.70 | — | — | |
| SCHEMBL839685 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20110124556-A1 | Insulin and IGF-1 Receptor Agonists and Antagonists | NOVO NORDISK A/S (DK) | 2011-05-26 | — | — | US | disclosed |
| US-20090192072-A1 | Insulin and IGF-1 Receptor Agonists and Antagonists | NOVO NORDISK A/S (DK) | 2009-07-30 | — | — | US | disclosed |
| US-20090192072-A1 | Insulin and IGF-1 Receptor Agonists and Antagonists | NOVO NORDISK A/S (DK) | 2009-07-30 | — | — | US | disclosed |
| US-20090053807-A1 | Insulin and IGF-1 Receptor Agonists and Antagonists | NOVO NORDISK A/S (DK) | 2009-02-26 | — | — | US | disclosed |
| US-20090053807-A1 | Insulin and IGF-1 Receptor Agonists and Antagonists | NOVO NORDISK A/S (DK) | 2009-02-26 | — | — | US | disclosed |
| US-20070265189-A1 | INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | US | disclosed |
| US-20070265189-A1 | INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | US | disclosed |
| US-7173005-B2 | Peptide sequences capable of binding to insulin and/or insulin- like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at | ANTYRA INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173005-B2 | Peptide sequences capable of binding to insulin and/or insulin- like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at | ANTYRA INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070004634-A1 | Insulin and IGF-1 receptor agonists and antagonists | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20070004634-A1 | Insulin and IGF-1 receptor agonists and antagonists | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124556-A1 | Insulin and IGF-1 Receptor Agonists and Antagonists | IGF1R, IGFBP1, IGFBP2 | HSP90AA1 1987/4885KDM4E 4487/4885NAPRT 3430/4885 |
| US-20090192072-A1 | Insulin and IGF-1 Receptor Agonists and Antagonists | IGF1R, IGFBP1, IGFBP2 | HSP90AA1 1987/4885KDM4E 4487/4885NAPRT 3430/4885 |
| US-20070265189-A1 | INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS | IGF1R, IGFBP1, IGFBP2 | HSP90AA1 1987/4885KDM4E 4487/4885NAPRT 3430/4885 |
| US-20070004634-A1 | Insulin and IGF-1 receptor agonists and antagonists | IGF1R, IGFBP1, IGFBP2 | HSP90AA1 1918/4885KDM4E 4500/4885NAPRT 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.